ArticleAntimicrobial agents and chemotherapy2018
Iron Restriction to Clinical Isolates of Candida albicans by the Novel Chelator DIBI Inhibits Growth and Increases Sensitivity to Azoles
Article in Antimicrobial agents and chemotherapy, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 52 citations in OpenAlex.
- Prochelators modulate azole activity againstRSC chemical biology · 2026Article
- Article
- The in vitro activity of iron chelator deferiprone against Candida (Candidozyma) auris in combination with antifungal agents.Medical mycology · 2025Article
- Leveraging Vulnerabilities in Copper Trafficking for Synergistic Antifungal Activity.ACS chemical biology · 2025Article
- Article
- Iron-MOFs for Biomedical Applications.Advanced healthcare materials · 2025Review
- Integrating ensemble machine learning and multi-omics approaches to identify Dp44mT as a novel anti-Frontiers in pharmacology · 2025Article
- Methicillin-resistant Staphylococcus pseudintermedius: epidemiological changes, antibiotic resistance, and alternative therapeutic strategies.Veterinary research communications · 2024Review
- Host-microbe interaction paradigms in acute and recurrent vulvovaginal candidiasis.Cell host & microbe · 2024Review
- Artemisinin May Disrupt Hyphae Formation by Suppressing Biofilm-Related Genes ofAntibiotics (Basel, Switzerland) · 2024Article
- Mind the Gap-A Perspective on Strategies for Protecting against Bacterial Infections during the Period from Infection to Eradication.Microorganisms · 2023Review
- A New Phenotype inmBio · 2023Article
- The Metabolism of Susceptibility: Clearing the FoG Between Tolerance and Resistance inCurrent clinical microbiology reports · 2023Article
- Potential additional effects of iron chelators on antimicrobial- impregnated central venous catheters.Frontiers in microbiology · 2023Article
- Synergy and Mechanism of Leflunomide Plus Fluconazole Against ResistantInfection and drug resistance · 2023Article
- Synergistic Effect of the Combination of Deferoxamine and FluconazoleAntimicrobial agents and chemotherapy · 2022Article
- Potential Use of Iron-Limiting Therapy against Cryptococcus neoformans and Effects of Caspofungin on the Host Immune System.mSphere · 2022Article
- Antimicrobial Activity of the Iron-Chelator, DIBI, against Multidrug-Resistant Canine Methicillin-SusceptiblePathogens (Basel, Switzerland) · 2022Article
- Pseudomonas Synergizes with Fluconazole againstInfection and immunity · 2022Article
- Augmenting Azoles with Drug Synergy to Expand the Antifungal Toolbox.Pharmaceuticals (Basel, Switzerland) · 2022Review
Corrections and comments
- Erratum issuedErratum for Savage et al., "Iron Restriction to Clinical Isolates of Candida albicans by the Novel Chelator DIBI Inhibits Growth and Increases Sensitivity to Azoles2019 · del Carmen Parquet, Maria [corrected to Parquet, Maria del Carmen]
Authors and funding
7 authors at 2 institutions in 2 countries.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.